Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

IDH1 Overexpression Induced Chemotherapy Resistance and IDH1 Mutation Enhanced Chemotherapy Sensitivity in Glioma Cells in Vitro and in Vivo

  • Wang, Ju-Bo (Department of Neurosurgery, First Affiliated Hospital of Medical College, Xi'An Jiao-tong University) ;
  • Dong, Dan-Feng (Department of Oncology, First Affiliated Hospital of Medical College, Xi'An Jiao-tong University) ;
  • Wang, Mao-De (Department of Neurosurgery, First Affiliated Hospital of Medical College, Xi'An Jiao-tong University) ;
  • Gao, Ke (Department of Neurosurgery, First Affiliated Hospital of Medical College, Xi'An Jiao-tong University)
  • Published : 2014.01.15
Download PDF
⟨ Previous Next ⟩

Abstract

Isocitrate dehydrogenase (IDH) is of great importance in cell metabolism and energy conversion. IDH mutation in glioma cells is reported to be associated with an increased overall survival. However, effects biological behavior of therapy of gliomas are unclear. Here, we investigated the influence of wild-type and mutated IDH genes on glioma cell biological behavior and response to chemotherapy. Relevant mechanisms were further explored. We designed our study on the background of the IDHR132H mutation. Stable cell lines were constructed by transfection. The CCK-8 method was used to assess cell proliferation, flow cytometry for the cell cycle and cell apoptosis, and the transwell method for cell invasion. Nude mouse models were employed to determine tumorigenesis and sensitivity to chemotherapy. Western blotting was used to detect relevant protein expression levels. We found that overexpression of wild IDH1 gene did not cause changes in the cell cycle, apoptosis and invasion ability. However, it resulted in chemotherapy resistance to a high dose of temozolomide (TMZ) in vivo and in vitro. The IDH1 mutation caused cell cycle arrest in G1 stage and a reduction of proliferation and invasion ability, while raising sensitivity to chemotherapy. This may provide an explanation for the better prognosis of IDH1 mutated glioma patients and the relative worse prognosis of their wild-type IDH1 counterparts. We also expect IDH1 mutations may be optimized as new targets to improve the prognosis of glioma patients.

Keywords

References

  1. Babu R, Sharma R, Karikari IO, et al (2012). Outcome and prognostic factors in adult cerebelar glioblastoma. J Clin Neurosci, 20, 1117-21.
  2. Baldewpersad Tewarie NM, Burgers IA, Dawood Y, et al (2013). NADP (+)-dependent IDH (R132) mutation and its relevance for glioma patient survival. Med Hypothesis, 80, 728-31. https://doi.org/10.1016/j.mehy.2013.02.022
  3. Buonerba C, Di Lorenzo G, Marinelli A, et al (2011). A comprehensive outlook on intracerebral therapy of malignant gliomas. Crit Rev Oncol Hematol, 80, 54-68. https://doi.org/10.1016/j.critrevonc.2010.09.001
  4. CBTRUS (2009-2010). Central Brain Tumor Registry of the US Statistical Report. Published by the Central Brain Tumor Registry of the United States.
  5. Chen Rx, Cui JF, Xu CD, et al (2012). The significance of MMP-9 over MMP-2 in HCC invasiveness and recurrence of hepatocellular carcinoma after curative resection. Ann Surg Oncol, 19, S375-84. https://doi.org/10.1245/s10434-011-1836-7
  6. Chen YN, Chen JC, Yin SC, et al (2002). Effector mechanisms of norcantharidin-induced mitotic arrest and apoptosis in human hepatoma cells. Int J Cancer, 100, 158-65. https://doi.org/10.1002/ijc.10479
  7. Combs SE, Gutwein S, Ertner DS, et al (2005). Temozolomide combined with irradiation as postoperative treatment of primary glioblastoma multiforme: Phase I/II study. Strahlenther Onkol, 181, 372-7. https://doi.org/10.1007/s00066-005-1359-x
  8. Dai CX, Zhang B, Liu XH, et al (2013). Pyrimethamine sensitizes pituitary adenomas cells to temozolomide through cathepsin B-dependent and caspase-dependent apoptotic pathways. Int J Cancer, 133, 1982-93. https://doi.org/10.1002/ijc.28199
  9. Dang L, White DW, Gross S, et al (2009). Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature, 462, 739-U52. https://doi.org/10.1038/nature08617
  10. Irena R, Jasminka JR, Velibor P, et al (2012). Prognostic value of matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9) and aminopeptidase N/CD13 in breast cancer patients. Med Oncol, 29, 561-9. https://doi.org/10.1007/s12032-011-9984-y
  11. Jansen MPHM, Reijm EA, Sieuwerts AM, et al (2012). High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer. Breast Cancer Res TR, 133, 937-47. https://doi.org/10.1007/s10549-011-1877-4
  12. Langers AMJ, Verspaget HW, Hawinkels LJAC, et al (2012). MMP-2 and MMP-9 in normal mucosa are independently associated with outcome of colorectal cancer patients. Br J Cancer, 106, 1495-8. https://doi.org/10.1038/bjc.2012.80
  13. Lewandowska MA, Furtak J, Szylberg T, et al (2013). An analysis of the prognostic value of IDH1 (isocitrate dehydrogenase 1) mutation in polish glioma patients. Mol Diagn Ther, 2, 785-96.
  14. Li RY, Chen LC, Zhang HY, et al (2013). MiR-139 inhibits Mcl-1 expression and potentiates TMZ-Induced apoptosis in glioma. CNS Neurosci Ther, 19, 477-83. https://doi.org/10.1111/cns.12089
  15. Nobusawa S, Watanabe T, Kleihues P, et al (2009). IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res, 15, 6002-7. https://doi.org/10.1158/1078-0432.CCR-09-0715
  16. Parsons DW, Jones S, Zhang X et al (2008). An integrated genomic analysis of human glioblastoma multiforme. Science, 321, 1807-12. https://doi.org/10.1126/science.1164382
  17. Quaranta M, Daniele A, Coviello M, et al (2007). MMP-2, MMP-9, VEGF and CA 15.3 in breast cancer. Anticancer Res, 27, 3593-600.
  18. Que XY, Li Y, Han Y, et al (2013). Effects of siRNA-mediated CDC2 silencing on MG63 cell proliferation and apoptosis. Mol Med Rep, 7, 466-70.
  19. Sherman JH, Hoes K, Marcus J, et al (2011). Neurosurgery for brain tumors: update on recent technical advances. Curr Neurol Neurosci Rep, 11, 313-9. https://doi.org/10.1007/s11910-011-0188-9
  20. Stupp R, Mason WP, van den Bent MJ, et al (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Eng J Med, 352, 987-96. https://doi.org/10.1056/NEJMoa043330
  21. Timme CR, Gruidl M, Yeatman TJ (2013). Gamma-secretase inhibition attenuates oxaliplatin-induced apoptosis through increased Mcl-1 and/or Bcl-xl in human colon cancer cells. Apoptosis, 18, 1163-74. https://doi.org/10.1007/s10495-013-0883-x
  22. Turcan S, Rohle D, Goenka A, et al (2012). IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature, 483, 470-U137. https://doi.org/10.1038/nature10807
  23. Wen PY, Kesari S (2008). Malignant gliomas in adults. N Engl J Med, 359, 492-507. https://doi.org/10.1056/NEJMra0708126
  24. Yan H, Parsons DW, Jin G, et al (2009). Idh1 and Idh2 mutations in gliomas. N Engl J Med, 360, 765-73. https://doi.org/10.1056/NEJMoa0808710
  25. Yang T, Zhang YL, Li YL (2013). High amounts of fluoride induce apoptosis/cell death in matured ameloblast-like LS8 cells by down regulating Bcl-2. Arch Oral Biol, 58, 1165-73. https://doi.org/10.1016/j.archoralbio.2013.03.016
  26. Yu CJ, Wang ZC, Wang ZY, et al (2008). Incidence of intracranial tumors. In 'Neurosurgery'. Chief Ed: Wang ZC. Hubei, Science and Technology Press, 512-8.

Cited by

  1. Increased Argonaute 2 Expression in Gliomas and its Association with Tumor Progression and Poor Prognosis vol.15, pp.9, 2014, https://doi.org/10.7314/APJCP.2014.15.9.4079
  2. Comparative transcriptomics reveals similarities and differences between astrocytoma grades vol.15, pp.1, 2015, https://doi.org/10.1186/s12885-015-1939-9
  3. Expression Profile Analysis of Zinc Transporters (ZIP4, ZIP9, ZIP11, ZnT9) in Gliomas and their Correlation with IDH1 Mutation Status vol.16, pp.8, 2015, https://doi.org/10.7314/APJCP.2015.16.8.3355
  4. ) in metastatic pancreatic cancer pp.1555-8576, 2016, https://doi.org/10.1080/15384047.2016.1210743
  5. O6-methyl-guanine-DNA methyltransferase methylation and IDH1/2 mutation in small cell lung cancer vol.14, pp.1, 2017, https://doi.org/10.3892/etm.2017.4476
  6. Biomarkers and therapeutic advances in glioblastoma multiforme pp.17437555, 2017, https://doi.org/10.1111/ajco.12756
  7. expression is associated with a poor prognosis in cytogenetically normal acute myeloid leukemia vol.137, pp.5, 2015, https://doi.org/10.1002/ijc.29395
  8. Methylation dependent down-regulation of G0S2 leads to suppression of invasion and improved prognosis of IDH1-mutant glioma vol.13, pp.11, 2018, https://doi.org/10.1371/journal.pone.0206552
  9. Wild-type and mutated IDH1/2 enzymes and therapy responses vol.37, pp.15, 2018, https://doi.org/10.1038/s41388-017-0077-z
  10. Metformin sensitizes endometrial cancer cells to chemotherapy through IDH1-induced Nrf2 expression via an epigenetic mechanism vol.37, pp.42, 2018, https://doi.org/10.1038/s41388-018-0360-7
  11. RNA N6-methyladenosine modification in cancers: current status and perspectives vol.28, pp.5, 2018, https://doi.org/10.1038/s41422-018-0034-6
  12. Predicting drug response of tumors from integrated genomic profiles by deep neural networks vol.12, pp.S1, 2019, https://doi.org/10.1186/s12920-018-0460-9